There is yet another multibillion-dollar deal in a consolidating pharmaceutical sector, as Roche Holding AG has agreed to buy United States biotech company InterMune Inc for $8.3 billion in cash.
Announced this past Sunday, Swiss company Roche will pay $74.00 a share for InterMune, a premium of 38 percent to the closing price on Aug. 22.
It will be interesting to see how this move pans out for Roche moving forward.
